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The increasing use of medical indwelling devices has triggered the development of 
difficult-to-treat infections due to biofilm formation on the implant surface. Nowadays, infection 
treatment consists of invasive surgical intervention combined with long-course systemic 
antimicrobial infusion. However, treatment failure due to ineffective surgical debridement and 
inappropriate antibiotic therapy is a troublesome reality. Hence, the development and formulation 
of novel smart biomaterials as scaffolds for the local release of drugs gained increasing interest. 
The aim of this work was to investigate the anti-biofilm and anti-persister activity of 
selected antimicrobials, to fine-tune the isothermal microcalorimetry (IMC) as antimicrobial 
susceptibility method and to study the formulation, release characteristics and antimicrobial 
activity of different biomaterials (including recently developed hydrogels) loaded with 
therapeutically relevant antimicrobials for the management of orthopedic implant-associated 
infections. 
Results showed that high concentrations of vancomycin enriched a Staphylococcus aureus 
biofilm in persister cells, which are mainly responsible for infection recalcitrance. It was reported 
that a deep analysis of IMC data enables the detection and identification in real-time of persister 
cells, proving the suitability of this method for the characterization of new anti-persister 
compounds and biomaterials. Interestingly, the combined use of the glycopeptide with daptomycin 
proved highly bactericidal against persisters. The lipopeptide was then successfully loaded into soft 
and fully degradable thermosensitive hydrogels, which released high concentrations of active drug 
(widely exceeding the minimum bactericidal concentration) in a controlled manner against S. 
aureus for at least 15 days. Similarly, high titers of bacteriophages were released from smart 
thermoresponsive hydrogels in a controlled manner for at least 7 days. As a comparison, also the 
gentamicin elution profile from bone graft substitutes was investigated, revealing a timely burst 
release of bactericidal concentrations. 
This work demonstrated that high doses of commonly used antibiotics may select for 
persister cells in biofilms. In fact, recalcitrance and extreme resistance of biofilm-associated 
infections affecting the musculoskeletal system are deeply influenced by metabolically inactive 
cells that, to the best of our knowledge, were here identified and characterized for the first time 
using IMC. Smart bioscaffolds may serve as drug reservoirs and offer optimal conditions for the 
release of high doses of anti-biofilm and anti-persister molecules in situ, providing relevant 
progress to the fast-growing field of biomaterials and advances towards their clinical application. 
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ABSTRAKT 
Die zunehmende Verwendung von medizinischen Verweilvorrichtungen hat die Entwicklung 
von schwer zu behandelnden Infektionen durch Biofilmbildung auf den Oberflächen von Implantaten 
bestimmt. Heutzutage besteht die Behandlung von Infektionen in einer Kombination aus operativen 
Eingriffen und systemischen antimikrobiellen Infusionen. Behandlungsversagen aufgrund ineffizienten 
chirurgischen Debridements und unpasssende antibiotische Therapie sind jedoch eine problematische 
Realität. Daher hat die Entwicklung und Formulierung neuartiger intelligenter Biomaterialien als Gerüst 
für die lokale Freisetzung von Arzneimitteln zunehmendes Interesse gefunden. 
Das Ziel dieser Arbeit war die Untersuchung der Anti-Biofilm- und Anti-Persister-Aktivität 
ausgewählter antimikrobieller Mittel, die Feinabstimmung der isothermen Mikrokalorimetrie (IMC) als 
antimikrobielle Suszeptibilitätsmethode und die Untersuchung antimikrobieller Potenziale diverser 
Biomaterialien, die mit therapeutisch relevanten Mitteln zur Behandlung von orthopädischen 
implantatassoziierten Infektionen beladen sind. 
Die Ergebnisse zeigten, dass hohe Konzentrationen von Vancomycin einen Staphylococcus 
aureus-Biofilm in Persisterzellen angereichert haben, die hauptsächlich für die Problemhaftigkeit der 
Infektionen verantwortlich sind. Eine gründliche Analyse von Daten der isothermen Mikrokalorimetrie 
(IMC) ermöglicht den Nachweis und die Identifizierung von persistenten Zellen in Echtzeit, was die 
Eignung dieser Methode für die Charakterisierung neuer anti-persistenter Verbindungen und 
Biomaterialien belegt. Interessanterweise erwies sich die kombinierte Verwendung des Glycopeptids 
mit Daptomycin als stark bakterizid gegen Persister. Das Lipopeptid wurde erfolgreich in vollständig 
abbaubare wärmeempfindliche Hydrogele geladen, die nachweislich auf kontrollierte Weise hohe 
Konzentrationen an Wirkstoff freisetzen, die die minimale bakterizide Konzentration gegen S. aureus 
für mindestens 15 Tage weit überschreiten. In ähnlicher Weise wurden hohe Titer von Bakteriophagen 
mindestens 7 Tage lang kontrolliert aus intelligenten thermoresponsiven Hydrogelen freigesetzt. Zum 
Vergleich wurde auch das Gentamicin-Elutionsprofil von Knochentransplantatersatzmitteln untersucht, 
was eine zeitnahe Freisetzung bakterizider Konzentrationen aufzeigt. 
Diese Arbeit zeigte, dass häufig verwendete Antibiotika in hohen Dosen persistente Zellen in 
Biofilmen selektieren können. Tatsächlich werden Rekalzitranz und extreme Resistenz von Biofilm- 
assoziierten Infektionen im Bewegungsapparat stark durch metabolisch inaktive Zellen beeinflusst, die 
hier zum ersten Mal mit IMC identifiziert und charakterisiert wurden. Intelligente Bioscaffolds können 
als Reservoir für Arzneimittel dienen und bieten optimale Bedingungen für  die  Freisetzung  hoher 
Dosen von Biofilm- und Anti-Persister-Molekülen in situ, was dem schnell wachsenden 




The raising use of medical indwelling devices, such as orthopedic joint prosthesis and 
artificial cardiac valves, has strongly improved life quality of patients and fostered longevity. 
However, this also carries the threatening evidence of the development of difficult-to-treat 
infections [1]. In the orthopedic field, the increasing number of implanted joint arthroplasties and 
fixation devices is associated to frequent cases of surgical infections, which represent a significant 
clinical, socio-economic and public burden [2]. Orthopedic implant-associated infections are 
mainly due to microbial colonization of abiotic surfaces [2] , which eventually evolves into 
biofilms (Figure 1), causing the onset of chronic infection. Within a biofilm, microbes develop  
into a complex community with functional and structural heterogeneity [3]. The early microbial 
attachment is usually mediated by cell surface components and, afterwards, when the newly- 
formed aggregate is growing in density and dimensions, further extracellular components (such as 
polysaccharides, DNA, proteins and lipids) foster microbial aggregation and stimulate the 
development of a slimy extracellular polymeric substance [4]. Therefore, slime-enclosed cells 
acquire extreme resistance to the action of host immunity and antimicrobial killing [5], as 
compared to free-floating cells. The most common bacteria isolated in bone and implant- 
associated infections are Staphylococcus aureus and coagulase-negative staphylococci, which 
account for more than 50% of periprosthetic infections [6], fracture fixation-associated and spinal 
implant-associated infections [7]. Other clinically relevant microorganisms include streptococci, 
enterococci and gram-negative rods like Escherichia coli, Pseudomonas spp. and Enterobacter 
spp. [8]. 
 
Figure 1 Schematic representation of a biofilm formed on a hip prosthesis. Biofilms are 
aggregates of different microbial cells, including susceptible and persister cells, embedded  
within a self-produced exopolymeric matrix. Planktonic cells are free-floating non-sessile cells 
that can spread and contaminate surrounding tissues and surfaces. 
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Along with normal-growing cells, bacterial biofilms host cells characterized by non- 
growing phenotypes, which are able to tolerate higher concentrations of bactericidal antibiotics 
[9], thus contributing to the recalcitrance of infection. In fact, even though the bactericidal 
treatment kills most of the susceptible cells in the sessile community, persisters survive and, upon 
treatment discontinuation, repopulate the biofilm [10]. Persister cells account for a small fraction 
of a microbial population, which is genetically susceptible but phenotypically tolerant to 
antimicrobials due to the non-growing quiescent state [11, 12]. In fact, persistence differs from 
resistance, which is a characteristic inherited by the whole microbial population and it entails the 
ability of bacteria to replicate in the presence of antimicrobials [13]. Although persisters mostly 
arise stochastically [14], their induction may also be promoted as protective response to particular 
stress conditions, like high antibiotic doses [15], as well as nutritional restrictions and oxygen 
depletion [16]. Indeed, levels of persisters frequently increase during stationary growth phase and 
in biofilms [17]. 
Bacterial tolerance and resistance [13] are key players in infection recalcitrance and 
therapeutic failure [18], along with the physical protection offered by the extracellular matrix. 
Hence, for an effective eradication of orthopedic biofilm-associated infections the resection of 
infected necrotic tissue through surgical debridement is associated to a long course systemic 
pharmacological therapy [19]. However, systemic antibiotic therapies expose patients to a number 
of severe side effects, besides offering low local concentrations and scarce tissue penetration. 
Hence, the combined use of local antimicrobials allows reaching high drug concentrations at the 
infection site, typically exceeding the minimum inhibitory concentrations (MICs) for most of 
bacteria [20], with low systemic toxicity [21]. Indeed, local drug release from bioscaffolds results 
in the optimization of the therapeutic effects associated to the drastic reduction of drug toxicity. 
Extensive research has targeted degradable biomaterials as drug releasing vehicles [22], 
which do not require follow-up surgeries after complete drug elution. For instance, collagen 
implants [23], bone graft substitutes [24] and bioactive glasses [25] have been investigated. Of 
different chemical composition and structure are hydrogels, highly hydrophilic cross-linked three- 
dimensional networks which proved to be excellent candidates for tissue engineering [26] and for 
the controlled release of antibiotics and other therapeutic agents [27, 28]. Injectable 
thermosensitive hydrogels can be delivered in a minimally invasive manner [29], then jellifying 
upon temperature to body temperature [30]. Additional to antibiotics, alternative antimicrobial 
agents like bacteriophages (virus exhibiting lytic activity against bacteria) [31] and   antimicrobial 
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peptides [32] can be encapsulated and efficiently released in therapeutically relevant quantities at 
the site of infection. 
Taken together, the smart combination of surgical approach, systemic infusion and local 
administration of antimicrobials via degradable bio-friendly scaffolds reflects the paramount 
effort needed for the prevention and treatment of complicated of bone and implant-associated 
infections. As many novel technological biomaterials still undergoes pre-clinical tests, it is 
predictable that a clinical revolution in the management of biofilm-associated infections is to 
come in the forthcoming years. 
 
 
2. AIM OF THE  THESIS 
 
The main aim of this work is to study the release and the in vitro activity of therapeutically 
relevant antimicrobial agents (i.e. antibiotics, bacteriophages) from novel biomaterials for the 
management of orthopedic implant-associated infections. Therefore, the main objectives are: 
1. To establish an accurate, non-destructive and highly sensitive in vitro analytical technique 
for assessing biofilm susceptibility to antimicrobials in real-time by monitoring bacterial viability 
(Study A: Butini et al., Real-time antimicrobial susceptibility assay of planktonic and biofilm 
bacteria by isothermal microcalorimetry. Advances in experimental medicine and biology  
(2018)); 
2. To investigate and characterize persister cells in a S. aureus biofilm after anti-biofilm 
treatment using isothermal microcalorimetry (IMC) and standard antimicrobial susceptibility 
methods (Study B: Butini et al., Isothermal microcalorimetry detects the presence of persister 
cells in a Staphylococcus aureus biofilm after vancomycin treatment. Manuscript submitted to 
Frontiers in Microbiology and currently under revision); 
3. To analyze release kinetics and anti-biofilm activity of antimicrobial and anti-persister 
agents eluted from novel fully degradable hydrogels (Study C: Casadidio1, Butini1 et al., 
Daptomycin-loaded biodegradable thermosensitive hydrogels enhance drug stability and foster 
bactericidal activity against Staphylococcus aureus. European Journal of Pharmaceutics and 
Biopharmaceutics (2018)) and resorbable bone graft substitutes (Study D: Butini et al., In vitro 
anti-biofilm activity of a biphasic gentamicin-loaded calcium sulfate/hydroxyapatite bone graft 
substitute. Colloids and Surfaces B – Biointerfaces (2018)). 
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3. MATERIALS  AND METHODS 
3.1. Storage and culture of bacterial strains 
 
Stocks of S. agalactiae ATCC 13813, methicillin-resistant S. aureus (MRSA) ATCC 43300, 
methicillin-susceptible S. aureus (MSSA) ATCC 29213, S. epidermidis ATCC 12228, 
Streptococcus pyogenes ATCC 19615, E. faecalis ATCC 19433 and E. coli Bj HDE-1 were stored 
in cryovial bead preservation system at -80 °C. Bacterial strains were cultured on Columbia Blood 
Agar for 24 h at 37 °C in an ambient air incubator, except for S. agalactiae and S. pyogenes,  
which were cultivated on Trypticase Soy Agar (TSA) supplemented with 5% defibrinated sheep 
blood for 18 h at 37 °C under 5% CO2 atmosphere. All bacterial liquid cultures were prepared in 
Trypticase Soy Broth (TSB). S. pyogenes and S. agalactiae were inoculated in TSB supplemented 
with 2.5% lysate horse blood (Study A and D). Antimicrobial assays were performed in Cation 
Adjusted Müller Hinton broth (CAMHB), whereas Brain Heart Infusion (BHI) broth was used to 
investigate bacteriophage lytic activity. 
3.2. Antimicrobial agents and biomaterials 
 
Daptomycin was obtained as a powder and dissolved in sterile Phosphate Buffered Saline (pH 7.4, 
10 mM) (Study B and C). Vancomycin was obtained as powder and reconstituted using sterile 
pyrogen-free water (Study B). Levofloxacin used in Study A was supplied in liquid form and the 
other antibiotics tested in Study B were supplied either as a powder or in liquid form from the 
Suppliers. Anti-staphylococcal bacteriophage Sb-1 were stored at 4 °C in 10 ml-vials as received 
from the suppliers. The titer of the bacteriophage solution was determined by plaque assay, as 
reported below. 
Vinyl sulfonated poly(N-(2-hydroxylpropyl)methacrylamide mono/di-lactate) (p(HPMAm-lac1,2)- 
PEG-poly(HPMAm-lac1,2)) triblock co-polymers with a 10% degree of substitution (DS (%)) 
(VinylSulfTC_n) were synthesized by the research group of Prof. Di Martino (University of 
Camerino, Italy) and provided in lyophilized form, as well as hyaluronic acid with different DS 
(HASH_n´). Polymers were used to formulated daptomycin-loaded hydrogels (Study C). 
A freeze-dried form of hyaluronic acid/poly(N- isopropylacrylamide) (pNIPAm) hydrogel was 
provided from AO Research Institute (Davos, Switzerland) and reconstituted with a bacteriophage 
solution (anti-staphylococcal Sb-1 bacteriophage) to formulate bacteriophages-loaded hydrogels. 
Four different types of sterile beads of gentamicin-loaded bone graft substitute 
(CERAMENT™|G), containing increasing amounts of gentamicin were provided by 
BONESUPPORT AB (Lund, Sweden) (Study D). 
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3.3. Real-time anti-biofilm activity assay by isothermal microcalorimetry (IMC) 
 
Study A reports on the convenient use of IMC as a real-time antimicrobial susceptibility assay. 
This non-conventional technique is an accurate and highly sensitive method that enables the 
continuous monitoring of microbial viability in terms of instantaneous heat produced due to the 
microbial metabolic activity. Moreover, IMC is a non-destructive method which do not require 
the use of toxic reagents and harsh mechanical manipulation, thus allowing the retrieval of tested 
samples for further analysis (plating/colony counting of biofilm cells after treatment). Besides 
validating the antimicrobial efficacy of drugs, IMC provided important advances also in the study 
of antimicrobial-loaded biomaterials, allowing undemanding sample preparation and fast 
monitoring of the microbial response to the released agent. Isothermal microcalorimetric analysis 
was performed using a TAM III-48 microcalorimeter (TA Instruments, New Castle, DE, USA) 
with a detection limit of heat production of 0.2 µW and equipped with 48 minicalorimeters. 
Sterile glass ampoules (4 ml-volume) were used and sealed for air tightness prior to introduction 
into the minicalorimeters. After 15 minutes of equilibration, ampoules were lowered in the 
measuring position. Heat flow (µW) and total heat (J) were measured in real-time against time (h) 
as measure of the instantaneous heat produced at any time point and as cumulative amount of  
heat produced during the experiment, respectively. Microbiologically relevant information, such 
as growth rate (µ, J/h) and lag phase (λ, h), were derived according to growth models [33]. (Study 
A) 
Porous glass beads were used as material support for biofilm formation during static incubation  
in inoculated rich medium for 24 h at 37 °C. After incubation, beads were washed with sterile 
saline and exposed to different concentrations of antibiotic or to antimicrobial-loaded biomaterial 
for 24 h in glass ampoules. A growth control consisting in untreated biofilm was included, as  
well as a sterile bead as negative control. Next, beads were retrieved, rinsed and placed in sterile 
ampoules containing fresh medium for IMC. 
To proceed with further analysis, treated biofilm beads were eventually collected, sonicated and 
analyzed by plating and colony counting of sonication fluids. 
3.4. Isolation and characterization of persister cells from S. aureus biofilms after 
vancomycin treatment and anti-persister activity of daptomycin 
To isolate staphylococcal persister cells (Study B), a 24 h-old biofilm grown on glass bead was 
exposed to high antibiotic concentrations (1024 µg/ml vancomycin) for 24 h. Next, rinsed beads 
were sonicated as described above to dislodge cells present after the treatment. Bacteria were 
diluted to a final concentration of ~1x105 CFUs/ml in PBS/1%CAMHB (to avoid any metabolic 
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re-activation, in case of persister cells), as previously described [11], and incubated at 37 °C with 
and without 100x minimum inhibiting concentration (MIC) of the tested antibiotic (100 µg/ml 
vancomycin). Staphylococcal cells dislodged from an untreated biofilm were inoculated (final 
concentration ~1x105 CFUs/ml) either in PBS/1%CAMHB or in CAMHB and used as cell 
viability controls. After 1, 3 and 6 h-incubation, samples were serially diluted and plated on   TSA 
for colony counting. The time needed for persisters to revert into normal-growing cells was 
monitored by real-time IMC. Briefly, bacterial biofilm was formed and treated as reported above. 
After sonication, bacteria were diluted to ~1x105 CFUs/ml and incubated in glass ampoules filled 
with fresh CAMHB. Untreated biofilm was sonicated as well and diluted free-floating bacteria 
incubated in CAMHB, as control. Heat flow (µW) and total heat (J) were monitored for 15 h at 37 
°C. 
A 24 h-old MRSA biofilm treated with high vancomycin concentrations (1024 µg/ml) for 24 h 
was further exposed to sub-eradicating concentrations of daptomycin (16 µg/ml). After treatment 
suspension and sonication, serial dilutions of the sonication fluids were plated for colony  
counting. (Study B) 
3.5. Daptomycin-loaded hydrogels formulation and daptomycin release in vitro 
 
In Study C, two different formulations of daptomycin-loaded hydrogels were prepared at a 
VinylSulfTC_10 final concentration of 15% w/v and at a HASH_n´ (DS 31 and 53%) final 
concentration of 5 and 3%, respectively. The concentration of active daptomycin released was 
determined by the agar well diffusion assay against MRSA (ATCC 43300) [34] and tested against 
a 24 h-old biofilm using IMC. 
3.6. Bacteriophages-loaded hyluronan hydrogels formulation and bacteriophages  release 
in vitro 
 
Bacteriophages-loaded hydrogels were formulated with a concentrated bacteriophage solution 
(Sb-1 initial titer ~8.5 x 108 Plaque Forming Units (PFUs)/ml) to a final concentration of 15% 
w/v. Then, PBS was added on top of the gels (gel:PBS volume ratio = 1:4) and gels were 
incubated at 37 °C. The titer of released bacteriophages was determined by plaque assay against 
MRSA [35] and expressed as PFUs/ml. 
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4. RESULTS 
This chapter contains key results published in Advances in experimental medicine and biology 
(2018) (Study A), European Journal of Pharmaceutics and Biopharmaceutics (2018) (Study C) 
and Colloids and Surfaces B – Biointerfaces (2018) (Study D). Key findings from Study B are 
reported in a manuscript that has been submitted to Frontiers in Microbiology and is currently 
under revision. 
 
IMC allows for the real-time evaluation of the anti-biofilm activity of antimicrobials 
against in vitro biofilm 
As reported in Study A, IMC enables the real-time monitoring of exothermic reactions associated 
to microbial metabolic activities in the presence or absence of an antimicrobial agent. As depicted 
in Figure 2A, the co-incubation of a 24 h-old MRSA biofilm with high concentrations of 
vancomycin (ranging from 256 to 1024 µg/ml) inhibited staphylococcal metabolism, as no heat 
flow was detectable during 24 h-incubation. By contrast, the untreated biofilm produced a first 
peak in heat flow (µW) within the first 4h. As soon as the antibiotic treatment was suspended 
(Figure 2B), the re-incubation of beads in fresh rich medium revealed the presence of residual 
biofilm cells, which re-started replicating. In fact, a heat flow related to cells’ metabolic 
reactivation was detected, although delayed in time. Indeed, as shown in Figure 2B, increasing 
vancomycin concentrations correlated to more delayed onsets of biofilm exponential metabolic 





Figure 2 IMC evaluation of anti-biofilm activity of vancomycin against MRSA biofilm in real- 
time (A) during and (B) after 24 h-treatment. Numbers represent vancomycin concentrations (in 
µg/ml) ranging from 256 to 1024 µg/ml. Zero represents an untreated control NC; negative 
(sterility) control. (Study B: Figure 5 in Butini et al., Manuscript submitted to Frontiers in 
Microbiology and currently under revision) 
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High concentrations of vancomycin select for persister cells in MRSA biofilm and 
daptomycin exerts an anti-persister activity in vitro 
Study B revealed that free-floating cells dislodged from treated biofilms and exposed to 
100xMIC vancomycin (P+V100xMIC) were not affected by high drug concentrations, as indicated 
by the steady number of colonies (~105 CFUs/ml) observed during 6h-incubation, similarly to  
the same bacterial sample derived from pre-treated biofilms, which were not challenged with 
100xMIC vancomycin (P) (Figure 3). By contrast, cells derived from biofilm without any drug 
pre-treatment (GC) showed an increase of 1.5log10 CFU/ml in comparison to the initial inoculum 




Figure 3 Characterization of persister cells isolated from MRSA biofilm after 24h-treatment with 
1024 µg/ml vancomycin. The effect of exposure to high bactericidal vancomycin concentrations 
(100xMICVAN = 100 µg/ml) was assessed by colony counting (Log10CFUs/mL) of persister cells 
(P; P+V100xMIC) during 6 h-incubation in PBS/1% CAMHB. GC, growth control; GC+V100xMIC, 
growth control treated with 100xMIC vancomycin. Data are expressed as mean ± SD, 3≤ n ≤6. 
(Study B: Figure 6 in Butini et al., Manuscript submitted to Frontiers in Microbiology and 
currently under revision) 
 
The same samples exposed to 100xMIC vancomycin (GC+V100xMIC) showed a reduction of ~ 
2.5log10 CFU/ml after 6h in comparison to the untreated GC (7.25±2.10x103 vs 2.47± 3.98x106 
CFUs/ml respectively), indicating a susceptibility to 100xMIC vancomycin higher than that 
observed P+V100xMIC sample. 
To deepen the investigation in Study B by evaluating persisters’ reversion to normal growth, 
dislodged treated and untreated biofilm cells (P and GC, respectively) were incubated in fresh 
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rich medium. As shown in Figure 4, GC rapidly reached the exponential growth phase (λ =3.8  
h), as suggested by the timely increase in heat flow, whereas P showed the characteristic delayed 
growth curve (λ =7 h) resembling the GC heat flow/time curve. Specifically, a ∆λ = 3.2 h was 
calculated between the first peaks of GC and P, suggesting that P cells remained in a 
metabolically inactive status and, after 6 hours (time needed for the heat flow to exceed the 




Figure 4 Characterization of persister cells isolated from MRSA biofilm after 24 h-treatment with 
1024 µg/ml vancomycin. Revival assay in CAMHB by IMC monitoring the heat flow (µW) 
plotted against time (h) produced during the experimental time (h). GC, growth control; P, 
persister cells; NC; negative (sterility) control. (Study B: Figure 7 in Butini et al., Manuscript 
submitted to Frontiers in Microbiology and currently under revision) 
 
Since vancomycin anti-biofilm monotherapy did not eradicate a 24 h-old staphylococcal biofilm,  
a staggered use of high doses of vancomycin (1024 µg/ml) and sub-eradicating concentrations of 




Figure 5 Evaluation of the eradicating activity of the combined staggered treatment 
vancomycin+daptomycin against a 24 h-old MRSA (ATCC 43300) biofilm by sonication and 
colony counting (Log10CFUs/mL). Numbers and letters indicate vancomycin (V) and  daptomycin 
(D) concentrations (in µg/ml). GC 72h; growth control of untreated 72 h-old biofilm. Data are 
expressed as mean ± SD, n = 3. (Study B: Figure 8 in Butini et al., Manuscript submitted to 
Frontiers in Microbiology and currently under revision) 
 
The bactericidal activity of daptomycin resulted in the complete killing of biofilm viable cells (0 
colonies on plate counts), highlighting a synergistic eradicating activity against a persister- 
enriched MRSA biofilm. By contrast, both vancomycin and daptomycin monotherapies failed in 
eradicating staphylococcal biofilm, since only a mild bactericidal activity resulted in ~2log10 
CFUs/ml reduction. 
 
Thermosensitive fully degradable hydrogels release high concentrations of daptomycin 
with retained anti-biofilm activity in a controlled manner 
Study C reports on the successful drug loading using daptomycin-saturated solutions (28 mg/ml, 
pH 4.5 and 8) to reconstitute the lyophilized polymers. During incubation at 37 °C, the material 
fully jellified, showing no flow behavior after approximately 4 h. 
Then, when gels were formulated using HASH_53 (3% w/v solid polymer content), a prominent 
and timely release of high amounts of lipopeptide, outreaching the minimum biofilm eradicating 
concentration against MRSA, was obtained (~1.3 mg/mL after 24 h), until hydrogel full 
degradation after 8 days of incubation (Figure 6A). Differently, hydrogels formulated with 
HASH_31 (5% w/v solid polymer content), consisting of higher cross-link density and lower 
network mesh size, retained higher drug loads but still releasing high concentrations (~600 
µg/mL)  that  widely  exceeded  the  MBC  during  15  days  of  incubation.  Taken  together,      a 
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cumulative release of ~60% and 40% of the initial amount of loaded drug was calculated for gels 




Figure 6 (A) Released active daptomycin and (B) cumulative release from hydrogels containing 
10% vinyl sulfonated triblock copolymer (VinylSulfTC_10) (15% w/v) and a varying amount of 
thiolated hyaluronic acid (3 and 5% w/v of HASH_31 (1) and 53 ( ), respectively) assayed by 
agar well diffusion method. Active daptomycin concentration (µg/mL) is plotted versus time 
(days), whereas the cumulative daptomycin release is expressed as percentage (%) over time 
(days).  MBEC,  minimum  biofilm  eradication  concentration;  MBC,  minimum      bactericidal 
concentration; MIC, minimum inhibiting concentration; (mean ± SD, n=3). (Study C: Figure 8 in 
Casadidio1, Butini1 et al., European Journal of Pharmaceutics and Biopharmaceutics (2018)) 
 
 
During co-incubation of MRSA biofilm with daptomycin-loaded hydrogels in microcalorimetric 
ampoules, a complete inhibition of biofilm metabolism-associated heat was observed, as  
compared to the growth control (~7x106 CFUs/mL by sonication/colony counting). Although a 
complete killing of biofilm cells was not achieved, as demonstrated by the detection of a delayed 
heat flow (maximum peak ~140 µW with a 7.5 h delay compared to the untreated biofilm), a 
major reduction in cell viability was monitored. Indeed, a 36% decrease of metabolism-related 
heat flow was detected in real-time (Study C: Figure 9 in Casadidio1, Butini1 et al., European 
Journal of Pharmaceutics and Biopharmaceutics (2018)). 
 
High titers of anti-staphylococcal bacteriophages are easily loaded and locally released 
from thermosensitive hydrogels 
With the future perspective of formulating double-antimicrobial controlled release systems, 
preliminary  tests   on  the  formulation  of   bacteriophages-loaded  hyaluronan   hydrogels    were 
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performed. In an experimental time of 7 days, a noteworthy prolonged and controlled release of 
Sb-1 was observed (Figure 7). 
 
 
Figure 7 Anti-staphylococcal bacteriophage Sb-1 release from bacteriophages-loaded hyaluronan 
hydrogels. The titer of released phages was monitored during 168 h-incubation at 37 °C and 
assessed by plaque assay. Sb-1 titers are expressed as Log10PFUs/ml against time (h). PFUs; 
plaque forming units. Data are expressed as mean ± SD, n = 5. 
 
Indeed, from an initial titer of 6.95±1.64x106 PFUs/ml upon buffer addition (T0), the 
concentration of released phages remained high throughout the whole experiment, decreasing to a 
minimum of 1.83±1.70x105 PFUs/ml after 7 days of incubation. A peak in phages release was 
monitored during the first 24 h-incubation, reaching a maximum of 4.52±2.13x108 PFUs/ml. 




Resorbable gentamicin-loaded bone graft substitutes quickly elute high concentrations of 
active gentamicin, strongly inhibiting biofilm viability of Gram-negative bacteria 
As observed with Study D, the incubation of biphasic hydroxyapatite/calcium sulfate beads gave a 




Figure 8 Release kinetic of active gentamicin from different combinations of gentamicin-loaded 
bone graft substitute beads (a–k) during 24 h-incubation at 37 °C under static conditions. 
Aliquots of release medium were sampled after 0, 1, 3, 6, 12 and 24 h-incubation. The 
concentration of active gentamicin (µg/mL) eluted in time (h) was calculated by agar diffusion 
assay. (Study D: Figure 1 in Butini et al., Colloids and Surfaces B – Biointerfaces (2018)) 
 
The observed high gentamicin concentrations released in the very first hours of incubation 
demonstrated to prevent, to different extent, the biofilm formation of different laboratory bacterial 
strains on glass bead. Indeed, Escherichia coli biofilm was prevented with remarkably low 
gentamicin concentrations (~12 µg/ml), considering that the bioavailability of the loaded drug is 
lower than that for free drug dissolved in aqueous solution, as conventionally tested. The loaded 
biphasic bone substitute also demonstrated a good anti-biofilm efficacy, in terms of reduction the 
metabolism-related heat of a 24 h-old biofilm of Gram-negative rods. Indeed, a strong bactericidal 
activity against E. coli biofilm was achieved with low gentamicin concentrations (~23 µg/ml). 
Differently, the preventive and bactericidal efficacy of released gentamicin against Gram-positive 





Chronic orthopedic infections are due to bacterial colonization of the surface of implanted 
devices, which evolves into biofilm, a microbial aggregate encased in an extracellular matrix and 
extremely resistant to the activity of host immunity and antibiotics [3]. The antibiotic 
susceptibility assay of biofilm-embedded cells is needed for the establishment of the best 
therapeutic regime. However, this test results rather laborious and time consuming. As 
demonstrated in Study A, the application of IMC allows for the real-time monitoring of bacterial 
viability in terms of heat production related to the cellular metabolic activity, proving to be a 
suitable method for the antimicrobial susceptibility of biofilm microorganisms. As expected, 
biofilm MRSA was tolerant to high concentrations of most of the tested antibiotics. In the past, 
the increased tolerance of biofilm bacteria to antibiotics was believed to be caused by the reduced 
permeability of the biofilm to drugs given by exopolymeric matrix [36]. Nevertheless, it was 
demonstrated that most antibiotics could efficiently penetrate biofilms in vitro [37], therefore 
supporting the hypothesis that a subpopulation of cells extremely tolerant to conventional 
antibiotics, referred to as peristers, could have a major role in treatment failure and relapse of 
infection [38]. To the best of our knowledge, with Study B we reported for the first time that a 
deeper analysis of IMC curves enables the detection and identification in real-time of persister 
cells within a biofilm after anti-biofilm treatment, proving that this technique is also suitable for 
the analysis and characterization of new anti-persister compounds and biomaterials. 
In particular, Study B showed that the scarce efficacy of vancomycin, when administered 
alone against a S. aureus biofilm in vitro, might be due to the selection of persister cells. Our 
observation was further confirmed by the IMC real-time monitoring of persisters’ growth 
reversion in fresh medium, which indeed revealed a diverse metabolic behavior, in terms of 
delayed metabolism resumption. If translated into clinical practice, this phenomenon might 
explain infection relapses leading to higher failure rates of vancomycin monotherapy [39]. Since 
persisters display a reduced replicating activity, the therapy should focus on compounds that are 
able to kill cells independently from the metabolic state [40]. Although the tolerance of S. aureus 
to daptomycin (as monotherapy) was reported in the literature [41], the lipopetide might exert a 
bactericidal activity against dormant cells by affecting the microbial outer membrane through 
rapid depolarization [42, 43]. As we observed, a sub-eradicating concentration of daptomycin (16 
µg/ml) was able to clear a staphylococcal biofilm infection enriched in persisters after 
vancomycin treatment, supporting the use of daptomycin in the clinical practice against MRSA 
infections after vancomycin treatment failure. 
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Given the evidence in Study B that daptomycin exerts an anti-persister activity, our 
interest focused on the effective loading of this molecule into biodegradable carriers for a 
controlled local release. Indeed, Study C provided new insights into the use of fully degradable 
biomaterials, such as hydrogels, as reservoir for the local release of antimicrobials as a safe 
therapeutic option for achieving high local drug concentrations without using invasive or  
harmful approaches, improving patient compliance and clinical outcomes. Hyaluronic 
acid/p(HPMAm-lac1,2)-based hydrogels are cross-linked networks of hydrophilic polymers that 
retain large amounts of water yet maintaining their three-dimensional structure. A first physical 
gelation is given by the hydrophobic interactions between the thermosensitive polymer chains 
(p(HPMAm-lac1,2)). Then, this newly-formed structure is further stabilized via the Michael 
Addition reaction, which occurs spontaneously at physiological conditions, between vinyl  
sulfone and thiol groups upon addition of thiolated hyaluronic acid as a cross-linker [30]. These 
type of gels proved tunable biodegradability profiles, fast gelation kinetics, tailorable mechanical 
properties and excellent biocompatibility [30]. The particular polymeric composition of these 
thermosensitive hydrogels used as daptomycin carrier favored a bimodal release profile, where 
~50% of loaded drug was released within the first 50 h-incubation following a diffusional release 
mechanism. Then, a second release phase followed a zero-order kinetic, providing a constant 
release of active daptomycin during the subsequent 13 days. This release mode based on an 
initial burst release followed by a sustained elution of high drug concentrations is remarkable. 
Indeed, differently from biomaterials characterized by a fast diffusion-driven bolus release (e.g. 
collagen-based gels [22]), the tested cross-linked hydrogels demonstrated to release the loaded 
compound with an initial burst release followed by a sustained drug elution up to polymer full 
degradation, possibly suppressing an early infection in the first stages of bacterial replication. 
Moreover, the hydrogel network exerted a protective activity on drug structure, limiting the 
formation of daptomycin degradation products and, consequently, fostering the retention of 
bactericidal activity, as observed by HPLC-MS analysis and microbiological assays performed 
against a laboratory strain of MRSA. 
Similar features characterize also different hydrogel formulations, for example the 
hyluronan/p(NIPAm)-based hydrogels, which were simultaneously formulated and loaded with 
lytic bacteriophages. Conceived to be applied mostly for the management of spinal infections or 
as implant coating, these gels released high phage titers for several days in a controlled manner, 
providing outstanding advances as alternative anti-biofilm strategy. Poly(NIPAm)-based 
hydrogels are attractive candidates for biomedical applications thanks to their high 
biocompatibility   and   thermosensitivity,   albeit   a   major   limitation   consists   in   the    non- 
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biodegradability of the polymeric backbone [44]. Hence, depending on the final intended clinical 
application, the choice of biomaterial varies based on its chemical composition and physical 
structure. For instance, the soft nature and hydrophilicity of cross-linked hydrogels can provide 
neither a mechanical support nor a solid scaffold for bone ingrowth. Nevertheless, injectable 
loaded hydrogels may serve as optimal carrier for the management of spinal implant-associated 
infections. 
As opposed to hydrogels, the mechanical stability and resistance offered by resorbable 
bone graft substitutes are essential characteristics for the application as bone void fillers. Thus, 
with Study D we aimed to compare the antimicrobial activity offered by loaded hydrogels to that 
of a commercially available gentamicin-loaded bone graft substitutes consisting of 
hydroxyapatite in a calcium sulfate matrix. Designed to fill bone voids and foster bone healing, 
the ceramic materials provide a stronger mechanical support by protecting and promoting a 
dynamic bone remodeling and formation, thus protecting the newly formed tissue from fractures 
and infections. In fact, together with gentamicin elution, the calcium sulfate matrix resorbs,  
being replaced by naturally regenerated bone within the hydroxyapatite scaffold. However, as 
observed during the 24h-release kinetic studies, the fast resorption of calcium sulfate might not 
allow for a controlled drug release comparable to what obtainable with hydrogels or other 
chemically cross-linked materials. Nevertheless, the combination of resorbable and soft fully 
degradable biomaterials may be applied, thus synergistically act for promoting the bone tissue 
healing and protecting the regenerative process via a rapid anti-persister activity. Indeed, 
although the mechanism of bactericidal action exerted by aminoglycosides is mostly effective 
against rapidly growing cultures, their ability to eradicate persister cells of Gram-positive and 
negative strains in vitro and in vivo has been enabled using specific metabolite stimuli [45]. 
With this thesis, the successful formulation and analysis of different biocompatible 
materials for orthopedic applications have been demonstrated. The bactericidal effect exerted by 
the combination of vancomycin with daptomycin was shown, revealing the anti-persister activity 
of the lipopeptide, which was then loaded and efficiently released from high-technology smart 
hydrogels. In addition, the investigation of thermosensitive hydrogels loaded with bacteriophages 
revealed a surprising long-lasting release of high titer and the convenient application of IMC was 
also demonstrated in many regards, deeply fostering the use of this technique in clinical 
microbiology and material science. Then, low doses of gentamicin eluted from a ceramic scaffold 
proved to prevent the formation of E. coli biofilm, besides also completely inhibit the growth of 
an established one. 
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Taken together, the reported findings suggest that the application of smart biomaterials 
such as antibiotic-loaded biphasic bone graft substitutes as bone void fillers, together with the 
local injection of thermosensitive hydrogels as degradable vehicles for the controlled release of 
antimicrobials (e.g. daptomycin and bacteriophages) may provide paramount improvements for 
the management of biofilm-associated infections affecting the musculoskeletal system, indeed 
promoting bone healing and protecting the tissue regeneration from (re)infections by killing any 
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